European Medicines Agency, London, United Kingdom.
Lægemiddelstyrelsen, København, Denmark; Agence Française de Sécurité Sanitaire des Produits de Santé, Saint-Denis, France; College ter Beoordeling van Geneesmiddelen and Medicines Evaluation Board, The Hague; Netherlands Cancer Institute, Amsterdam; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
On June 14, 2010, the European Commission issued a conditional marketing authorization valid throughout the European Union for pazopanib for the treatment of advanced renal cell carcinoma. Pazopanib is an antineoplastic agent that inhibits multiple receptor tyrosine kinases. The recommended oral dose is 800 mg once daily. The benefit of pazopanib is an increased progression-free survival. In the pivotal trial VEG105192, the median progression-free survival was 9.2 months (95% confidence interval, 7.4-12.9) in the pazopanib arm compared with 4.2 months (95% confidence interval, 2.8-4.2) in the placebo arm. The most common side effects include diarrhea, hair color change, hypertension, nausea, fatigue, anorexia, vomiting, dysgeusia, elevated alanine aminotransferase, elevated aspartate aminotransferase, and abdominal pain. The objective of this article is to summarize the scientific review of the application that led to approval in the European Union.
Written by:
Nieto M, Borregaard J, Ersbøll J, Ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F. Are you the author?
Reference: Clin Cancer Res. 2011 Nov 1;17(21):6608-14.
doi: 10.1158/1078-0432.CCR-11-1734
PubMed Abstract
PMID: 21976546
UroToday.com Renal Cancer Section
